Page 9 - Read Online

Hughes et al. Rare Dis Orphan Drugs J 2024;3:29 https://dx.doi.org/10.20517/rdodj.2024.30 Page 3 of 3

As we further explore the multifaceted landscape of Fabry disease through this Special Issue, we are pleased
to announce the upcoming release of Book 2, which will further enrich our understanding and provide a
comprehensive view of the complexities associated with this disorder. This anticipated volume will tackle
critical aspects crucial for both clinicians and researchers committed to improving the lives of those affected
by Fabry disease.

DECLARATIONS
Authors’ contributions
Conception, design, and writing of the article: Hughes D, Pintos-Morell G

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
Both authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2024.

REFERENCES
1. Anderson W. A case of “ANGEIO-KERATOMA”. Br J Dermatol 1898;1:113-7. DOI
2. Fabry J. Ein Beitrag zur Kenntniss der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae) Arch Dermatol
Syph 1898;43:187-200. DOI
3. de Duve C. Tissue fraction-past and present. J Cell Biol 1971;50:20. PubMed
4. Brady RO, Gal AE, Bradley RM, Martenson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase
deficiency. N Engl J Med 1967;276:1163-7. DOI PubMed
5. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for
diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003;138:338-46. DOI PubMed
6. Schiffmann R. Investigating Fabry disease - some lessons learned. Rare Dis Orphan Drugs J 2024;3:4. DOI
7. Feriozzi S, Rozenfeld P. The inflammatory pathogenetic pathways of Fabry nephropathy. Rare Dis Orphan Drugs J 2024;3:11. DOI
8. Aguiar P. Biomarkers in anderson-Fabry disease: what should we use in the clinical practice? Rare Dis Orphan Drugs J 2024;3:13.
DOI
9. West ML, Geldenhuys L, Bichet DG. Fabry nephropathy: a treatable cause of chronic kidney disease. Rare Dis Orphan Drugs J
2024;3:22. DOI
10. Politei JM, Solar B. Gastrointestinal involvement in Fabry disease. Rare Dis Orphan Drugs J 2024;3:10. DOI
11. Moreno-Martínez D, León-Cejas L, Reisin R. Cerebrovascular disorders and Fabry disease. Rare Dis Orphan Drugs J 2024;3:9. DOI